中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

137 records (took 0.036 seconds)

    SYRINGE ASSEMBLY WITH ION-EXCHANGE MATERIAL
    1.
    发明申请
    SYRINGE ASSEMBLY WITH ION-EXCHANGE MATERIAL 审中-公开

    公开(公告)号：WO2019097003A1

    公开(公告)日：2019-05-23

    申请号：PCT/EP2018/081588

    申请日：2018-11-16

    Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)

    Inventor： FRANSSON, Jonas

    IPC: A61M5/19 ,  A61K9/00 ,  A61J1/20 ,  A61M5/32 ,  A61M5/31

    CPC classification number: A61M5/19 ,  A61J1/2093 ,  A61K9/0019 ,  A61M5/329 ,  A61M2005/3128

    Abstract: A pre-filled syringe is disclosed, comprising a barrel and a plunger, the barrel having an outlet, the barrel containing a pharmaceutically acceptable solution having a non-physiological pH, wherein the syringe further comprises an ion exchange material. The ion exchange material is provided at a position to allow contact with the pharmaceutically acceptable solution upon ejection of the pharmaceutically acceptable solution from the barrel via the outlet. The ion exchange material is capable of adjusting the pH of the solution from a non-physiological pH, at which the pharmaceutically acceptable solution is stored in order to ensure acceptable shelf life, to a more physiological pH at which the discomfort and/or pain experienced during injection may be alleviated.

    MODIFIED SULFAMIDASE AND PRODUCTION THEREOF
    3.
    发明申请
    MODIFIED SULFAMIDASE AND PRODUCTION THEREOF 审中-公开
    改性磺化酶及其生产

    公开(公告)号：WO2015150490A1

    公开(公告)日：2015-10-08

    申请号：PCT/EP2015/057256

    申请日：2015-04-01

    Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)

    Inventor： BERGHARD, Charlotta ,  NORDLING, Erik ,  SVENSSON GELIUS, Stefan ,  TJERNBERG, Agneta

    IPC: C07K14/435

    CPC classification number: C12N9/14 ,  A61K38/00 ,  C12N9/96 ,  C12Y310/01001

    Abstract: Disclosed herein are a modified sulfamidase, a composition comprising a modified sulfamidase, as well as methods for preparing a modified sulfamidase and therapeutic use of such a sulfamidase. In particular, the present disclosure relates to a modified sulfamidase comprising substantially no epitopes for glycan recognition receptors, thereby enabling transportation of said sulfamidase across the blood brain barrier of a mammal, wherein said sulfamidase has catalytic activity in the brain of said mammal.

    Abstract translation: 本文公开了改性的磺酰胺酶，包含改性的磺酰胺酶的组合物，以及制备修饰的磺酰胺酶的方法和这种磺酰胺酶的治疗用途。 具体地说，本公开内容涉及基本上不含聚糖识别受体的表位的修饰的磺酰胺酶，从而使所述磺酰胺酶能够跨越哺乳动物的血脑屏障传递，其中所述的磺酰胺酶在所述哺乳动物的脑中具有催化活性。

    IMPROVED FORMULATIONS OF RECOMBINANT HUMAN BILE SALT-STIMULATED LIPASE
    4.
    发明申请
    IMPROVED FORMULATIONS OF RECOMBINANT HUMAN BILE SALT-STIMULATED LIPASE 审中-公开
    重组人类白细胞浸润脂质体的改进配方

    公开(公告)号：WO2013048313A1

    公开(公告)日：2013-04-04

    申请号：PCT/SE2012/051011

    申请日：2012-09-25

    Applicant: SWEDISH ORPHAN BIOVITRUM AB (PUBL)

    Inventor： EK, Vilhelm

    IPC: A61K38/46 ,  A61K9/19 ,  A23C9/152 ,  C12N9/18

    CPC classification number: C12N9/96 ,  A23L33/40 ,  A61K9/0095 ,  A61K9/19 ,  A61K38/465 ,  A61K47/183 ,  A61K47/26 ,  C12N9/18 ,  C12N9/20 ,  C12Y301/01001 ,  C12Y301/01013

    Abstract: The present invention relates to improved formulations of recombinant human bile salt stimulated lipase (rhBSSL), including those suitable for forming a lyophilized formulation of rhBSSL, lyophilized formulations of rhBSSL per-se, unit dose forms of rhBSSL and reconstituted formulations of rhBSSL. The formulations of the present invention comprises rhBSSL, a crystalline bulking agent and an amorphous stabilizer that is a different chemical entity to said crystalline bulking agent. The formulations of the present invention have one or more desired properties, including those that relate to stability, decreased aggregation and/or formation of insoluble aggregates in solution. The lyophilized formulations of the present invention have pharmaceutical utility, particularly for the administration of rhBSSL to human infants.

    Abstract translation: 本发明涉及重组人胆汁盐刺激的脂肪酶（rhBSSL）的改进制剂，包括适于形成rhBSSL的冻干制剂，rhBSSL本身的冻干制剂，rhBSSL的单位剂量形式和rhBSSL的重组制剂的那些。 本发明的制剂包括rhBSSL，结晶填充剂和与所述结晶填充剂不同的化学实体的无定形稳定剂。 本发明的制剂具有一种或多种所需的性质，包括与溶液中的不溶性聚集体的稳定性，减少的聚集和/或形成有关的性质。 本发明的冻干制剂具有药用效用，特别是用于向人类婴儿施用rhBSSL。

    A METHOD AND DEVICE FOR THE SERIAL EJECTION OF TWO FLUIDS COMPRISING A SPACER
    7.
    发明申请
    A METHOD AND DEVICE FOR THE SERIAL EJECTION OF TWO FLUIDS COMPRISING A SPACER 审中-公开
    用于包含间隔物的两种流体的串联喷射的方法和装置

    公开(公告)号：WO2009067082A1

    公开(公告)日：2009-05-28

    申请号：PCT/SE2008/051336

    申请日：2008-11-21

    Applicant: BIOVITRUM AB (publ) ,  FRANSSON, Jonas ,  HJERTMAN, Birger

    Inventor： FRANSSON, Jonas ,  HJERTMAN, Birger

    IPC: A61M5/28 ,  A61M5/19 ,  A61M5/315

    CPC classification number: A61M5/284 ,  A61M5/31501 ,  A61M5/31596 ,  A61M2005/1787 ,  A61M2005/3132

    Abstract: A device for the serial ejection of at least two fluid components comprises a spacer (19) providing at least two states, i)a first state allowing a front piston (7) to be displaced forwards by action on a rear piston (17) while a fluid volume is retained in a rear chamber (5) and ii) a second state allowing the rear chamber to volumetrically shrink while fluid is transferred past (or through) the front piston thereby enabling the use of a liquid, initially provided in only the rear chamber, for the dual purposes of mixing and rinsing.

    Abstract translation: 用于串联喷射至少两个流体部件的装置包括提供至少两个状态的间隔件（19），i）允许前活塞（7）通过作用在后活塞（17）上向前移位的第一状态，同时 流体体积被保留在后室（5）中，并且ii）允许后室在流体通过（或通过）前活塞传递（或通过）活塞时容积收缩的第二状态，从而能够使用液体，其最初仅在 后室，用于混合和冲洗的双重目的。

    ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN
    9.
    发明申请
    ADENOSINE DERIVATIVES FOR THE TREATMENT OF PAIN 审中-公开
    用于治疗疼痛的腺苷衍生物

    公开(公告)号：WO2008000745A3

    公开(公告)日：2008-04-17

    申请号：PCT/EP2007056378

    申请日：2007-06-26

    Applicant: BIOVITRUM AB PUBL ,  HIGGINBOTTOM MICHAEL ,  SAVORY EDWARD DANIEL ,  BROWN GILES ALBERT ,  HORGAN VIET-ANH ANNE NEE NGUYE ,  CHAPMAN EMMA JANE

    Inventor： HIGGINBOTTOM MICHAEL ,  SAVORY EDWARD DANIEL ,  BROWN GILES ALBERT ,  HORGAN VIET-ANH ANNE NEE NGUYE ,  CHAPMAN EMMA JANE

    IPC: C07H19/16 ,  A61K31/7076 ,  A61P25/04

    CPC classification number: C07H19/16

    Abstract: Compounds of formula (I) are disclosed. Their use as medicaments is described, in particular for the treatment of pain or inflammation. In said Fomula, when X=Y=Z=OH, R 1 is OCH 2 CF 2 CF 3 , phenoxy (substituted with 3-(4-trifluoromethylphenyl), 3,4-dichloro, (3-trifluoromethyl,4-fluoro), (3-trifluoromethyl,4-chloro), (3-chloro, 4-cyano), or 3,5-bis(trifluoromethyl)), 1-piperazinyl(4-(3,4-dichlorophenyl)), phenyl (substituted with 3,4-dichloro, 3,5-difluoro, 3,5-bis(trifluoromethyl) or 3,4,5-trifluoro) or 2-benzofuranyl; or when X=Y=OH and Z=OMe, R 1 is OCH 3 , OCH 2 CHF 2 , OCH 2 cyclopentyl, O-(2,5- difluorophenyl) or (S)-sec-butylamino; or when X=H and Y=Z=OH, R 1 is n-hexylamino or cyclopentylamino; or when (IV) X=Z=OH and Y=H, R 1 is cyclopentylamino;or a pharmaceutically acceptable salt thereof.

    Abstract translation: 公开了式（I）的化合物。 描述了它们作为药物的用途，特别是用于治疗疼痛或炎症。 在所述的Fomula中，当X = Y = Z = OH时，R 1是CH 2 CH 2 CH 2 CF 3 ，苯氧基（被3-（4-三氟甲基苯基），3,4-二氯，（3-三氟甲基，4-氟），（3-三氟甲基，4-氯），（3-氯，4-氰基） （三氟甲基）），1-哌嗪基（4-（3,4-二氯苯基）），苯基（被3,4-二氯，3,5-二氟，3,5-双（三氟甲基）或 3,4,5-三氟）或2-苯并呋喃基; 或当X = Y = OH且Z = OMe时，R 1是OCH 3，OCH 2 CHF 2， ，OCH 2 - 环戊基，O-（2,5-二氟苯基）或（S） - 仲丁基氨基; 或当X = H且Y = Z = OH时，R 1是正己基氨基或环戊基氨基; 或当（IV）X = Z = OH且Y = H时，R 1是环戊基氨基;或其药学上可接受的盐。

Patent Agency Ranking